GET DAILY SIGNALSPliant Therapeutics (PLRX) Q3 2026 Earnings Preview: What the Expected Loss Signals for Investors
Key Takeaways
- Pliant Therapeutics (PLRX) is expected to report its third-quarter 2026 results around November 5, 2026, with Wall Street consensus pointing to a net loss of -$0.37 per share.
- The company is a clinical-stage biopharmaceutical developer, meaning revenue is minimal and the spotlight will fall squarely on operating expenses, cash burn, and clinical program updates.
- In the same period a year earlier, PLRX reported a loss of -$0.43 per share; last quarter (Q2 2026), it posted -$0.36, narrowly missing the -$0.34 consensus estimate.
- PLRX has beaten consensus EPS estimates in 5 of its last 8 quarters, but the stock has traded well below its 50-day and 200-day moving averages heading into this report.
- Investors will focus on the company's cash position, reported at roughly $158 million in the most recent quarter, and management's commentary on how far that capital will carry its pipeline.
- For more information on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, be sure to explore the dedicated pages for a fuller picture.
- You can also discover market opportunities using Trending AI Robots, which apply AI-driven signals to identify active trading ideas across the market.
Why This Earnings Report Matters
Pliant Therapeutics develops integrin-based therapies aimed at regulating cell communication and tissue remodeling. As a clinical-stage company with little to no product revenue, the quarterly update centers less on sales growth and more on spending discipline, clinical advancement, and balance-sheet strength. The stock has fallen sharply over the past year, resulting in a modest market cap that makes every data point and management comment carry extra weight. In my view, this release serves as a checkpoint on whether remaining cash can support key programs through their next milestones and whether recent strategic shifts are gaining traction.
What Analysts Expect This Quarter
Wall Street anticipates a net loss of about -$0.37 per share for the third quarter of 2026, an improvement from the -$0.43 per share loss recorded a year earlier. Revenue forecasts remain essentially zero given the company’s stage. For context, Q2 2026 produced a -$0.36 per share loss that missed the -$0.34 consensus by two cents, while Q1 2026 came in at -$0.32 and beat the -$0.36 estimate. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Historically, the share price has responded to both the magnitude of the loss and any pipeline commentary, with research-and-development spending trends and cash-consumption rates among the metrics drawing the most attention.
Current Market Sentiment
Investor sentiment ahead of the report appears cautious. PLRX has been hovering near its 52-week low and below both the 50-day and 200-day moving averages, reflecting ongoing selling pressure. Analyst ratings sit at a consensus “Hold,” with price targets spread across a wide range. From what I see, the main risks include the pace of cash burn relative to runway, timing of clinical readouts, and any potential need for additional financing. A tighter expense outlook or clearer milestone path could ease some pressure, whereas signs of faster spending or delayed catalysts might extend the downward trend.
What to Watch Beyond the Numbers
Looking ahead, capital adequacy remains the central issue. With roughly $158 million in cash on the latest balance sheet and continued research-and-development outlays, investors will listen closely for updated runway guidance and any hints about future financing needs. Clinical execution will matter just as much, including enrollment updates and expected data readouts across the pipeline. One thing that stands out is how any partnership or restructuring news could alter the longer-term narrative. Cost trends in both research-and-development and general-and-administrative areas will also indicate whether management is extending the runway while prioritizing high-value assets.
AI Screener in My Research Workflow
I frequently rely on Tickeron’s AI Screener to quickly scan biopharma names and benchmark setups like PLRX against peers. The tool lets me apply filters for fundamentals, technical patterns, and AI signals in one place, saving time and surfacing comparable opportunities without manual effort. It has become a regular part of how I prepare for events like this earnings release.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for PLRX turns negative, indicating new downward trend
PLRX saw its Momentum Indicator move below the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned negative. In 79 of the 87 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for PLRX crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for PLRX entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PLRX's RSI Indicator exited the oversold zone, 26 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for PLRX just turned positive on November 03, 2026. Looking at past instances where PLRX's MACD turned positive, the stock continued to rise in 33 of 46 cases over the following month. The odds of a continued upward trend are 72%.
Following a +4.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where PLRX advanced for three days, in 197 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
PLRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. PLRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.344) is normal, around the industry mean (2.904). P/E Ratio (-0.544) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. PLRX's P/S Ratio (3333.333) is slightly higher than the industry average of (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PLRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in the business of developing and commercializing novel therapies for fibrotic diseases
Industry Biotechnology
Advertisement